In 2020, the peripheral neuropathy (PN) research community achieved a huge breakthrough. For the first time, Congress included “peripheral neuropathy” as an eligible condition for study in the Department of Defense’s (DoD) Peer Reviewed Medical Research Program (PRMRP). This secured more than $8 million in grants for peripheral neuropathy research in fiscal year 2021. Our […]
The Foundation for Peripheral Neuropathy (FPN) is continuing its peripheral neuropathy advocacy campaign in 2022, to make funding available for research on peripheral neuropathy. FPN (and the scientific community) were pleased to see that over $8 million was awarded to research focused on PN. Additionally, this funding was provided under the Department of Defense’s (DoD) […]
Read More… from Call to Action 2022! We Need to Keep Our Voices Loud!
The Foundation for Peripheral Neuropathy is pleased to announce that peripheral neuropathy has been renewed as an eligible condition for Department of Defense (DOD) funds for the upcoming year. The Bill recently made it into law and FPN is proud that its lobbying campaign this past year was a success! Peer-Reviewed Medical Research Program The […]
The Department of Defense’s (DoD) Peer-Reviewed Medical Research Program (PRMRP) has determined the grant applications that it wishes to award in fiscal year 2021 (FY21). In this first year that applications were accepted for research in peripheral neuropathy, 41 applications out of over 1000 applications received focused on peripheral neuropathy. DoD is recommending awarding a grant […]
Last week, the Chairman of the Senate Committee on Appropriations released the Majority’s draft of the fiscal year 2022 (FY22) Defense Appropriations Act. The Foundation for Peripheral Neuropathy is pleased to see that this draft legislation once again includes “peripheral neuropathy” among the eligible conditions for grants in FY22 from the Department of Defense’s Peer […]
Read More… from Peripheral Neuropathy is Again an Eligible Condition for DOD Grants
Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates and the Foundation for Peripheral Neuropathy’s advocacy consultant in Washington, D.C., confirmed that the president and Congressional leaders recently reached an important two-year budget deal, paving the way for the Senate to complete its spending bills in September. As a result, in early September, the […]
Read More… from Call to Action! Help Us Get Your Voice Heard for More Research Funding!
On July 9, 2018, the Federal Drug Administration (FDA) held a public forum focusing on the patient’s perspective on drug development for chronic pain. The FDA invited members of the public, including the Foundation for Peripheral Neuropathy’s (FPN) President, Lou Mazawey, to attend to give their perspectives on living with chronic pain and treatment approaches […]
Read More… from FDA and FPN survey patients on chronic pain and treatments
On December 3, 2015, Astellas Pharma US, Inc. (the U.S. affiliate of Astellas Pharma Inc.), a R&D-driven global pharmaceutical company, invited the Foundation for Peripheral Neuropathy to present to a global team working on development of ASP3662 for patients with neuropathic pain (NP). This was an internal meeting, which included Ulf Tollemar, Executive Director, Development […]